BMSEHA15
Haematologica, Vol 95, Issue 2, 339-340 doi:10.3324/haematol.2009.016956
Copyright © 2010 by Ferrata Storti Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Remacha, A. F.
Right arrow Articles by Pedro, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remacha, A. F.
Right arrow Articles by Pedro, C.

Myelodysplastic Syndromes

Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment

Angel F. Remacha, Beatriz Arrizabalaga, Javier Bueno, Juan Muñoz, Joan Bargay, Carme Pedro

Complejo Hospitalario Toledo; Hospital de Cruces Baracaldo (Vizcaya); Hospital Vall d’Hebrón, Barcelona; Hospital Puerta del Mar, Cádiz; Hospital Son Llatzer, Palma de Mallorca, Hospital del Mar, Barcelona, Spain

Correspondence: Ángel F. Remacha, Complejo Hospitalario de Toledo, Hematology Department, Avenida Barber, Toledo, Spain. Phone: international +34.9.658249752. Fax: international +34.9.25269303. E-mail: aremacha{at}sescam.jccm.es

Key words: myelodysplastic syndrome, erythropoietin, immunosuppression, mycophenolate.

Anemia is present in most patients with low-risk MDS (LR-MDS).1 Supportive treatment with transfusions was the final outcome of most of them, and transfusion-dependency is a prognostic factor for poor survival.2 A number of studies have demonstrated that, overall, one third of LR-MDS responded to growth factor treatment. A score system was developed3 which, according to transfusion requirements and serum erythropoietin levels, identifies cases with high or low probability of response.3,4 One important aspect is that the response to growth factors is not maintained, with a median duration of 24 months. However, only 20% of patients had a response which lasted more than four years.5

One important aspect, frequently forgotten, is that many LR-MDS are elderly handicapped patients. In fact, the number of patients lost during treatments was as high as 20% in studies using Epo+/–G-CSF-G, which only required subcutaneous injections.3,4

Immunological disturbances have been proposed to be among the mechanisms involved in MDS pathogenesis. As in aplastic anemias, in MDS abnormal SMD stem cells trigger an immunological cellular response which in turn attacks abnormal stem cells causing more damage to the remaining stem cells. This finding is probably the physiological basis for anti-lymphocytic gammaglobulin +/–cyclosporine responses.6 In MDS patients with trisomy 8, an expansion of a number of CD8 T-lymphocyte repertoires have been demonstrated, suggesting their involvement in the pathogenesis of MDS. In patients with refractory anemia, HLA-DR 15 and trisomy 8, the rate of response was 70%.7,8 However, the immunosuppressive treatment is not well tolerated and requires hospital admission.9

The purpose of this work was to rescue LR-MDS patients who had lost their response to Epo, or to treat patients with low probability of response to Epo using the Scandinavian Score.3 A therapeutical approach using sequentially immunosuppresion and growth factors was investigated. Mycophenolate mofetil and prednisone were used as immunosuppression because mycophenolate mofetil is given orally and is very well tolerated.10

The trial scheme (www.clinicaltrials.gov. Identifier: ML20559) used mycophenolate mofetil (Cell Cept) 1 g twice a day orally and oral prednisone 0.5 mg/Kg/d tapering prednisone to 10 mg/d. Mycophenolate mofetil and prednisone 10 mg were maintained to the end of the study. Response was evaluated at 12 weeks. In patients without major erythroid response, subcutaneous 30,000 U/week of recombinant human erythropoietin beta (Neorecormon) was added during six weeks. This was increased to 60,000 U/week in case of no major response following the IWG criteria.11

A total of 10 patients were treated (Table 1), including 8 cases that had received erythroid stimulating agents and had lost their response and 2 with high levels of serum erythropoietin. Seven of them were under transfusions. In one case the treatment was stopped because of pneumonia at two weeks. In 5 out of the 9 remaining cases, a response was observed; in 3 this was a major response (in one case under transfusions at the end of the study Hb was 96 g/L without transfusions, in one case with initial Hb of 81 g/L, Hb was 109 g/L after treatment, and in a case under transfusion final Hb was 97 g/L without transfusions). A minor response was seen in 2 patients (in one case the amount of transfusions was reduced from 6 units/month to 2 units, and in one case without transfusions Hb increased from 85 g/L to 101 g/L). Treatment was well-tolerated; 3 cases showed grade 1–2 diarrhea, in one case with diabetes mellitus an increase in diabetes treatment was required, and one case was admitted to hospital due to pneumonia.


View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		Table 1. Clinical characteristics and response to immunosuppression and growth factors treatment.

In spite of the low number of cases included, this treatment with oral immunosuppresion followed by addition of growth factors, as antiapoptotic agents, obtained a good rate of response. It is worth remembering that the cases included were patients with few alternative treatments. This approach is easy to manage and well-tolerated, and does not require hospital admission.

In summary, using the scheme of oral immunosuppresion and growth factors, in 3 out of the 9 LR-MDS patients transfusions were no longer required. Obviously, larger studies should be carried out to confirm and validate this scheme of treatment. Immunosuppression and growth factors could be an alternative to new drugs that have appeared recently.


arrow
References
TOP
 References
 
  1. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997;89 12: 4248–67.[Free Full Text]
  2. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23 30: 7594–603.[Abstract/Free Full Text]
  3. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al, Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120 6: 1037–46.[CrossRef][Web of Science][Medline]
  4. Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, Fernandez Fuertes I, Gonzalez FA, Font L, Junca J, del Arco A, Malcorra JJ, Equiza EP, de Mendiguren BP, Romero M. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 1999;84 12: 1058–64.[Abstract/Free Full Text]
  5. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005;106 3: 803–11.[Abstract/Free Full Text]
  6. Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophisiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009;94 4: 449–51.[Free Full Text]
  7. Shimamoto T, Ohyashiki K. Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma 2003;44 4: 593–604.[CrossRef][Web of Science][Medline]
  8. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005;106 3: 841–51.[Abstract/Free Full Text]
  9. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003;101 6: 2156–8.[Abstract/Free Full Text]
  10. Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 2005;75 1: 60–4.[CrossRef][Web of Science][Medline]
  11. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al, World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96 12: 3671–4.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Remacha, A. F.
Right arrow Articles by Pedro, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remacha, A. F.
Right arrow Articles by Pedro, C.